What the bemotrizinol decision actually changed, and what it does not mean for peptides
Peptide Product Wholesale Amp Peptide The decision amended an existing OTC monograph. It was not a new drug approval, and it created no pathway, category or precedent for any peptide.
The instrument matters because it explains the evidence burden. Bemotrizinol entered Monograph M020 through a final administrative order under section 505G(b)(1) of the Food and Drug Act, に掲載されました the Federal Register notice の 10 6月 2026. The process began with a Tier 1 OTC Monograph Order Request from DSM Nutritional Products LLC, announced in the December 2025 proposed order, and the final order grants that company and its licensees an 18-month exclusivity period from the effective date, に記載されているように the final administrative order itself.
The conditions of use show how specific a monograph entry is. 下 the amended monograph, a finished product must reach a minimum SPF of 2, may not combine bemotrizinol with aminobenzoic acid or trolamine salicylate, and is limited to oil, lotion, cream, gel, butter, paste, ointment, stick and spray forms where the propellant never contacts the formulation. FDA’s own framing, including the HHS Secretary’s comment that the ingredient “has been used safely in Europe for decades,” appears in FDA’s announcement.
Read the order as a QC reviewer and the lesson is plain. FDA rejected the aerosol spray data not because the ingredient failed, but because the stability programme behind it was too thin to evaluate: ten weeks of data, no release-time assay results, uncertain container impermeability, and storage conditions without humidity control. The submission was judged on the completeness of its evidence, not on the promise of its molecule.
Three groups read this differently. Suppliers see a reminder that the dossier is the product. Brand developers see a longer qualification checklist. QC and regulatory affairs, where most of our readers sit, see the actual work: deciding what evidence to demand and how to check that it connects.
Classify before you test: cosmetic, OTC drug, または両方
Classification is a claims decision, not a property of the molecule. A peptide is not automatically a drug, and it is not automatically a cosmetic.
FDA decides that by intended use. A cosmetic is an article applied to the body for cleansing, beautifying, promoting attractiveness or altering appearance. A drug is an article intended to diagnose, cure, mitigate, treat or prevent disease, or to affect the structure or function of the body. A product with both kinds of intended use must comply with both sets of requirements, and the term “cosmeceutical” has no meaning in U.S. law.
That has direct consequences for what you have to hold. MoCRA’s adequate safety substantiation requirement obliges the responsible person to keep records supporting safety, but neither the statute nor FDA regulations prescribe which tests to run. 別途, facility registration renewal every two years and annual product listing apply to cosmetic facilities and products, and serious adverse events must be reported within the 15-business-day serious adverse event clock.
Before you commission a single study, answer three questions in writing:
-
What exactly will the label and marketing claim the product does?
-
Does any claim cross into affecting structure or function, or preventing a condition?
-
If the answer to question two is yes, which drug requirements will the product carry?
Confirm the classification with regulatory counsel before the evidence plan is fixed. Reclassifying after the studies are designed usually means repeating them.
The five things a peptide data package must prove
The framework is not ours to invent, and it is not an FDA rule for cosmetics. It follows the logic of I Q2(R2)’s fit-for-purpose standard, which requires a validation protocol written before the study and treats identity, 純度, assay and impurity testing as separate procedure types. The edition in force is the March 2024 最終バージョン, which replaced the older Q2(R1) framework. For cosmetic peptides this is borrowed logic, applied because it works, not because the law demands it.
The scope of “peptide” is wider than many formulators assume. あ 2026 peer-reviewed safety framework for cosmetic peptides defines a peptide as a polymer of up to 40 アミノ酸, だいたい 4.4 kDa, and notes that historically cosmetic peptides have sat below 500 そして, around five residues. It also lists the modifications that must be defined rather than assumed: D-アミノ酸, glycosylation, and fatty-acyl conjugation at the N-terminus.
身元: confirming the molecule, not the trade name
Identity is a separate procedure type under Q2(R2), and it is the claim most often satisfied by a trade name and a certificate. That is not identity.
Ask for mass confirmation against theoretical mass by LC-MS, plus a second orthogonal technique. A single mass measurement tells you the dominant species has the expected mass; it does not tell you the material is pure or that the content is right. Mass spectrometry also confirms mass and fragmentation pattern, not stereochemistry, so a sequence containing D-amino acids needs its own evidence.
The sequence itself belongs in the package as a change-controlled document with a version history. An N-terminal modification is part of the molecule’s identity, not a cosmetic detail, so a palmitoylated peptide and its unmodified parent are different substances with different identity records.
純度: what an HPLC percentage leaves out
An area-percent figure from reversed-phase HPLC is a relative measure produced Real Peptides by one method on one instrument. It is not a property of the lot in isolation.
The number means something only alongside the method it came from: カラム, 勾配, 検出波長, reference standard and the lot-linked chromatogram. Without those, a reviewer cannot re-examine the result, そして 98 percent figure cannot be distinguished from a 95 percent one measured under different conditions. Area percent also cannot separate co-eluting truncation from oxidation without orthogonal evidence, which is why the chromatogram matters more than the headline.
Ask for the chromatogram and the method description, not the summary number. If the supplier cannot produce a lot-specific chromatogram, the purity claim is unverifiable regardless of its value. The validation protocol Q2(R2) requires should also exist before the study, not be reconstructed afterwards.
Content and counterion: why net peptide per milligram is a separate number
Net peptide content is the mass of peptide per milligram of material, and it is not the same as purity. あ 95 percent pure lot can still deliver far less peptide per milligram than the formulator assumes.
Two things sit between purity and content. 水, measured by Karl Fischer, and the counterion. Counter ions are an impurity class to characterise, and the framework names acetic acid as an example. In practice the counterion is often trifluoroacetate, and trifluoroacetate is heavy: it adds mass that is not peptide. Our own cosmetic peptide documentation treats trifluoroacetate as the default and offers acetate, chloride and ammonium exchange, because the counterion changes the net peptide figure per milligram and the formulator needs the number that matches the salt actually shipped. Planetpeptide
Determine peptide content with a suitable quantitative method, such as validated amino-acid analysis, qNMR or another justified assay. State the water, counterion and reporting basis where relevant; amino-acid analysis is not the only permissible method.
安定性: designing the study before the launch date
Stability is a study design problem, and the design has to be fixed before the launch date is set. Retrofitting timepoints after a launch plan exists is how programmes end up with data that cannot support the shelf life claimed.
The stress-testing logic in ICH Q1A(R2) is the right starting framework. 質問1A(R2)’s stress-testing purpose is to identify likely degradation products, establish degradation pathways and intrinsic stability, and validate that the analytical methods can actually detect change. Conditions include temperatures 10 °C above the accelerated condition, 湿度, 酸化, photolysis, and hydrolysis across a wide pH range.
Design the finished-formulation stability study around its composition, packaging, storage conditions and proposed shelf life. Pharmaceutical Q1A(R2) conditions may inform a study where justified; its submission durations, batch counts and significant-change definitions are not automatic cosmetic requirements.
These are drug-substance and drug-product conditions, borrowed as a framework. Cosmetics are not bound by them, and a cosmetic peptide programme can justify a lighter design. What it cannot do is skip the design step. Decide the storage conditions, the timepoints, the attributes tested and the acceptance criteria in writing, and make sure the methods used are stability-indicating before the first sample goes on test.
Callout: what the sunscreen order shows about thin stability data. FDA’s rejection of the aerosol spray data turned on exactly these elements: too short a study, no release-time results, storage conditions without humidity, and assay results close to the acceptance limit with no baseline to interpret them. A cosmetic peptide dossier will not be reviewed by FDA in the same way, but the same gaps make a package unreadable to any technical reviewer.
Where the peptide’s function can be measured, Q5C’s potency logic is worth borrowing: when intended use is linked to a measurable biological activity, potency testing belongs in the stability studies. Q5C itself applies to well-characterised proteins and polypeptides from biological sources, not to synthetic cosmetic peptides, so treat the principle as a design input rather than a requirement.
Labeling: getting the name and the order right
For US ingredient declarations, use the name required by the applicable labeling rules, including established or common/usual names and the relevant naming hierarchy. Parenthetical international alternatives may be acceptable in some cases, but every ingredient does not universally require a second INCI name in parentheses.
Ordering follows the 1%-and-below rule that lets peptide traces sit in any order. Ingredients are listed in descending order of predominance, and anything at 1 percent or less may be listed in any order after those above 1 パーセント. Proprietary “X (そして) Y” mixtures must be split into their components, which matters when a peptide arrives as a pre-blended stock.
The minimum connected data package, フィールドごとに
A connected data package is a set of lot-specific records that a reviewer can follow from the certificate of analysis back to the raw data. A certificate of analysis on its own is a summary, and a summary is not a package.
The connecting thread is data integrity. MHRA’s data-integrity guidance sets out the attributable, 読みやすい, 同時代の, オリジナル, accurate principles, extended by complete, 一貫性のある, 永続的で利用可能な, and states there is no difference in expectations whichever acronym is used. Raw data is the original record. If the chromatogram in the dossier cannot be traced to the run that produced it, the record is not connected.
Callout: the CoA-only answer. When a supplier responds to a documentation request with a certificate and nothing else, treat it Peptide Info Manufacturer as an incomplete answer rather than a refusal. Name the specific records you need and ask for them against the lot number you are evaluating.
Electronic records raise the bar further if the product crosses into drug territory. Part 11’s records-equivalence test makes electronic records trustworthy and generally equivalent to paper when the criteria are met, and requires the systems and controls to be available for FDA inspection. For a cosmetic-only product this is a useful benchmark rather than an obligation, but a supplier whose records would fail it is a supplier whose data you will struggle to audit.
Qualifying a peptide supplier before a U.S. launch
Cosmetic peptide supplier qualification comes down to one question: can this supplier produce lot-specific evidence on request, and does the evidence connect? Facility size and portfolio breadth do not answer it.
Our standard cosmetic peptide documentation pairs analytical HPLC for purity, mass spectrometry for identity, and peptide content with a certificate of analysis, chromatogram and mass spectrum for the lot. 対イオン分析, カール・フィッシャーによる水分含有量, endotoxin testing and optical rotation are available as additions. What matters in qualification is not the list but whether you can obtain it for the specific lot and whether the underlying method descriptions come with it.
Three checks we suggest running before an order:
-
Ask for a lot-specific package, not a template. Request the chromatogram, spectrum and content result for the lot you would receive, and compare the lot number across every document. Polypeptid Supplier
-
Ask how the sequence is controlled. A change-controlled sequence document with modification history tells you whether an N-terminal change would reach you as a new identity or as a silent substitution.
-
Ask what happens at scale-up. Purity and content can shift between milligram and kilogram scale, so ask for the analytical results from the largest scale run available and for the per-step testing that supports them.
Callout: tech-transfer risk. A package that is complete at small scale and silent at production scale leaves the brand developer carrying the risk. Ask which analytical results exist at the scale you will buy, and whether the method transfers with the process.
決定ルール: what to require before you commit
Do not commit to a peptide launch on a purity figure. Commit when the five claims are each supported by lot-specific, connected evidence, and not before.
Before commercial commitment, resolve safety, identity and other critical evidence gaps. Plan remaining development work with milestones appropriate to the stage; an early sample order need not already include every finished-formulation study.
実際に, that means an ordered sequence of requirements:
-
Written classification of the product and its claims, confirmed with regulatory counsel.
-
A change-controlled sequence document including every modification.
-
Identity by mass confirmation plus one orthogonal technique, on the lot.
-
Purity with the method description and the lot-linked chromatogram.
-
Net peptide content by a suitable quantitative method, with the reporting basis stated.
-
A stability protocol agreed in writing before the launch date is fixed, with stability-indicating methods.
-
A labeling review covering legally appropriate ingredient names and declaration order.
-
Records that trace from the certificate back to raw data.
よくある質問
Does the bemotrizinol decision create a route for peptide actives in the U.S.?
いいえ. The order amended an existing OTC sunscreen monograph under section 505G(b)(1) and applies to one UV filter under defined conditions. It establishes no pathway, category or precedent for peptides, cosmetic or otherwise. The transferable lesson is the evidence standard, not the legal route.
Is a peptide automatically regulated as a drug in the U.S.?
いいえ. FDA classifies by intended use, so the same peptide can be a cosmetic, a drug, or both depending on what the product claims. A product with both cosmetic and drug intended uses must comply with both sets of requirements, and there is no “cosmeceutical” category in U.S. law.
Is 98 percent HPLC purity enough for a U.S. launch?
It is one of five claims, and on its own it is not enough. A purity figure says nothing about identity, 正味ペプチド含有量, stability or whether the method was fit for purpose. Ask for the chromatogram, the method description and the content result alongside it.
純度と正味ペプチド含有量の違いは何ですか?
Purity is a relative measure of how much of the detected material is the target peptide. Net peptide content is the mass of peptide per milligram of the material, after water and counterion are accounted for. A high-purity lot with a heavy counterion can deliver substantially less peptide per milligram than the purity figure suggests.
Do cosmetic peptides have to meet ICH stability requirements?
いいえ. 質問1A(R2) and Q5C are drug and biological-product guidelines and are not legally binding on cosmetics. Their logic is still worth borrowing, because a stability protocol designed on those principles answers the questions a technical reviewer will ask.
What should a peptide certificate of analysis include?
少なくとも, the lot number, the analytical results for identity, purity and content, the methods used, and the specification each result is measured against. It should be accompanied by the lot-specific chromatogram and mass spectrum, and traceable to the underlying raw data.
結論
The bemotrizinol milestone is worth reading closely, but not as a sign that peptide access just got easier. It is a demonstration that U.S. access follows a connected, claim-by-claim data package, and that a submission is judged on the completeness of its evidence rather than the promise of its molecule. ペプチド開発者向け, that is a higher bar than most current documentation clears, and it is the right one to adopt before a launch date is set.
The practical takeaway is the decision rule: five claims, five sets of evidence, one connected record per lot. Classification first, then identity, 純度, コンテンツ, stability and assay suitability, each with the method and the raw data behind it. A supplier who can meet that standard for the lot you are buying is a supplier you can build a U.S. launch on.
At MOL Changes we supply cosmetic peptides from milligram research quantities to kilogram scale, with analytical HPLC, mass spectrometry and peptide content results issued against the lot, と対イオン, water content and endotoxin testing available where the application needs them. If you are assembling a documentation package ahead of a U.S. launch, send us your requirements and we will walk through what the lot records contain.
Publisher disclosure: MOL Changes supplies peptide services and has a commercial interest in this topic. Service ranges and capability statements are supplier claims; availability and performance for a specific construct require project-specific evidence.
